David K Singh, MD
Cardiac Electrophysiology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 7
- 4 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health · The Queens Medical Center. That is not proof they admit you there this week.
Plans that list them
7 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Singh’s office at (650) 962-4690 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
7 of 7 plans
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- The Queens Medical CenterHonolulu, HIAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of The Queens Health Systems, which runs 4 hospitalsPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.34 (1.12 to 1.55), Jul 2022 – Jun 2024Worse than the national rate — Iatrogenic pneumothorax rate: 0.47 (0.29 to 0.65) · 11,638 cases, Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.32 (3.74 to 6.9) · 3,569 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.79 (1.36 to 2.23) · 10,444 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.453, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.427, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.345, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for The Queens Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 3 the same, 2 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.34 (1.12 to 1.55) | Worse | Jul 2022 – Jun 2024 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.47 (0.29 to 0.65) · 11,638 cases | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.32 (3.74 to 6.9) · 3,569 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.79 (1.36 to 2.23) · 10,444 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.453 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.427 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.345 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0.12 to 1.78) · 2,583 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.61 (147.16 to 216.07) · 200 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 101 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 266 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 619 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.3 · 815 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 1,115 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 7,459 cases | None | Jul 2024 – Jun 2025 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.11 to 0.45) · 12,099 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.17 (0 to 2.44) · 1,411 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.9 (1.73 to 4.06) · 3,175 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.07 (2.95 to 11.2) · 1,400 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.22 (1.54 to 6.91) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.45 (0.06 to 2.83) · 821 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 163 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.143 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 501 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 1,438 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.8 · 272 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5 · 698 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 15.4 · 799 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 1,657 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5.1 to 8.6) · 477 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (9.1 to 13.9) · 477 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.4 · 122 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 17.5 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (10 to 16.1) · 2,546 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 768 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,104 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 52% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$64,221
Medicare paid this office $64,221 for 544 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 14 | $9,952 | $711 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 213 | $5,713 | $20 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 85 | $5,296 | $19 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $5,072 | $390 |
| Return visit (30+ min) | 47 | $4,119 | $70 |
See all 13 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 14 | $9,952 | $711 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 213 | $5,713 | $20 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 85 | $5,296 | $19 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $5,072 | $390 |
| Return visit (30+ min) | 47 | $4,119 | $70 |
| Return visit (30+ min) | 32 | $3,126 | $98 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 88 | $2,874 | $26 |
| New patient visit (45+ min) | 26 | $2,670 | $103 |
| New patient visit (45+ min) | 16 | $2,166 | $135 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,552 | $103 |
| Insertion of heart rhythm monitor under skin | 11 | $663 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 52 | $303 | $5 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 11 | $137 | $11 |
Procedures Medicare counted
| Pacemaker insertion or repair | 19 | More than 70% of doctors who do this |
Who their Medicare patients are
544 Original Medicare patients in 2024. Average age 78 · Under 65 4% · 85 and older 27% · Women 43% · Also on Medicaid 6% · Health risk score 1.95. Above the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 1.8.
Conditions among them: High blood pressure 75% · Atrial fibrillation 65% · Coronary heart disease 48% · Heart failure 47% · Chronic kidney disease 47% · Diabetes 39% · Stroke 17% · Cancer 16% · COPD 16% · Dementia 13% · Depression 12%.
The office billed $283,083, Medicare allowed $83,125 and paid $64,221; for 1,041 services of 42 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 544 | 1,041 | 78 | 1.95 | $283,083 | $64,221 |
| 2023 | 706 | 1,432 | 78 | 1.93 | $305,864 | $89,999 |
| 2022 | 717 | 1,625 | 77 | 1.88 | $292,623 | $88,653 |
| 2021 | 658 | 1,562 | 76 | 1.71 | $239,935 | $91,005 |
| 2020 | 370 | 1,132 | 75 | 1.92 | $299,290 | $109,912 |
| 2019 | 385 | 1,221 | 75 | 2.05 | $274,917 | $100,177 |
| 2018 | 370 | 1,279 | 74 | 1.95 | $310,795 | $112,098 |
| 2017 | 350 | 1,320 | 74 | 1.85 | $310,792 | $112,902 |
| 2016 | 320 | 910 | 73 | 1.93 | $249,332 | $91,301 |
| 2015 | 269 | 856 | 73 | 2.00 | $186,408 | $67,140 |
| 2014 | 226 | 879 | 73 | 1.71 | $203,804 | $75,456 |
| 2013 | 196 | 634 | 73 | 1.79 | $194,872 | $72,558 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 18 | $13,509 | $751 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 252 | $9,223 | $23 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 20 | $8,158 | $408 |
| Return visit (30+ min) | 66 | $5,726 | $74 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 84 | $5,403 | $20 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 13 | $5,358 | $244 |
| New patient visit (45+ min) | 44 | $4,338 | $99 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 99 | $4,322 | $28 |
| Return visit (30+ min) | 18 | $1,686 | $70 |
| New patient visit (45+ min) | 12 | $1,312 | $109 |
| New patient visit (30+ min) | 20 | $1,286 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 159 | $1,137 | $6 |
| Insertion of heart rhythm monitor under skin | 16 | $1,116 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,105 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 45 | $554 | $12 |
2022: 18 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 13 | $11,663 | $897 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 230 | $9,542 | $24 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $6,829 | $427 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 107 | $5,087 | $29 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 63 | $5,029 | $20 |
| Return visit (30+ min) | 51 | $4,508 | $80 |
| New patient visit (45+ min) | 29 | $2,836 | $98 |
| Return visit (30+ min) | 34 | $2,410 | $67 |
| New patient visit (45+ min) | 20 | $1,807 | $90 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 182 | $1,359 | $6 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 64 | $1,082 | $17 |
| New patient visit (30+ min) | 13 | $901 | $69 |
| Insertion of heart rhythm monitor under skin | 12 | $803 | $67 |
| Short return visit (20+ min) | 19 | $738 | $37 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 50 | $714 | $12 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 25 | $535 | $15 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 29 | $474 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 29 | $111 | $4 |
2021: 18 services
| Return visit (30+ min) | 115 | $11,156 | $83 |
| Long return visit (40+ min) | 56 | $8,315 | $128 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 157 | $5,435 | $25 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $4,813 | $438 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 136 | $4,699 | $22 |
| New patient visit (45+ min) | 32 | $3,603 | $113 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 44 | $3,089 | $21 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 72 | $3,044 | $30 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 12 | $2,744 | $229 |
| Short return visit (20+ min) | 55 | $2,733 | $47 |
| New patient visit (60+ min) | 13 | $2,058 | $158 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 201 | $1,501 | $6 |
| New patient visit (30+ min) | 19 | $1,335 | $70 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 14 | $1,327 | $95 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 57 | $1,252 | $22 |
| Programming of dual lead pacemaker system | 23 | $1,104 | $41 |
| Insertion of heart rhythm monitor under skin | 13 | $878 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 36 | $491 | $12 |
2020: 20 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 16 | $16,230 | $902 |
| Short return visit (20+ min) | 178 | $10,805 | $47 |
| Return visit (30+ min) | 70 | $6,628 | $76 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 21 | $5,554 | $241 |
| New patient visit (30+ min) | 55 | $3,901 | $71 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 20 | $2,763 | $120 |
| New patient visit (45+ min) | 19 | $2,361 | $124 |
| Programming of dual lead pacemaker system | 40 | $2,070 | $45 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 67 | $1,653 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 40 | $1,188 | $21 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,106 | $61 |
| Programming of multiple lead implantable defibrillator system | 14 | $997 | $59 |
| Programming of single lead implantable defibrillator system | 15 | $970 | $54 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 28 | $771 | $25 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 18 | $687 | $19 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 17 | $664 | $19 |
| Programming of dual lead implantable defibrillator system | 11 | $632 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 43 | $586 | $13 |
| Telehealth originating site facility fee | 22 | $510 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 61 | $450 | $7 |
2019: 18 services
| Short return visit (20+ min) | 139 | $9,518 | $57 |
| New patient visit (45+ min) | 60 | $7,636 | $127 |
| Return visit (30+ min) | 67 | $6,398 | $77 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $6,379 | $399 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 179 | $3,903 | $14 |
| New patient visit (30+ min) | 41 | $3,624 | $88 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 14 | $3,271 | $234 |
| Programming of dual lead pacemaker system | 41 | $2,559 | $53 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 17 | $1,972 | $116 |
| Programming of single lead implantable defibrillator system | 17 | $1,376 | $53 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 46 | $1,299 | $23 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,266 | $60 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 14 | $965 | $20 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 22 | $905 | $35 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 25 | $772 | $25 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 14 | $505 | $10 |
| Evaluation of cardiac rhythm monitor system | 11 | $435 | $33 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 21 | $217 | $10 |
2018: 21 services
| Return visit (30+ min) | 172 | $20,513 | $82 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 17 | $15,438 | $908 |
| New patient visit (45+ min) | 57 | $7,133 | $125 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 26 | $7,123 | $264 |
| Short return visit (20+ min) | 100 | $6,229 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 169 | $3,823 | $13 |
| Programming of dual lead pacemaker system | 42 | $2,932 | $44 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,298 | $85 |
| New patient visit (60+ min) | 14 | $2,170 | $155 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 17 | $2,142 | $119 |
| Implantation patient-activated heart monitoring device | 11 | $1,688 | $153 |
| Long return visit (40+ min) | 13 | $1,582 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,546 | $59 |
| Programming of dual lead implantable defibrillator system | 12 | $1,423 | $62 |
| Programming of multiple lead implantable defibrillator system | 13 | $1,360 | $68 |
| Programming of single lead implantable defibrillator system | 12 | $867 | $41 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 14 | $764 | $42 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 27 | $758 | $22 |
| Evaluation of cardiac rhythm monitor system | 14 | $534 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 13 | $376 | $24 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 18 | $193 | $10 |
2017: 23 services
| Return visit (30+ min) | 163 | $21,523 | $76 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 16 | $16,359 | $909 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 30 | $10,070 | $315 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 13 | $8,789 | $676 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $5,529 | $425 |
| Short return visit (20+ min) | 64 | $4,056 | $58 |
| Programming of dual lead pacemaker system | 53 | $3,840 | $46 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 171 | $3,756 | $13 |
| Long return visit (40+ min) | 26 | $2,773 | $103 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 21 | $2,625 | $119 |
| New patient visit (45+ min) | 22 | $2,609 | $119 |
| Programming of heart rhythm stimulation after drug infusion | 13 | $1,686 | $130 |
| Programming of single lead implantable defibrillator system | 19 | $1,531 | $45 |
| Programming of dual lead implantable defibrillator system | 13 | $1,465 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,037 | $52 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 16 | $856 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 28 | $850 | $21 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $793 | $50 |
| Programming of single lead pacemaker system | 12 | $600 | $43 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 15 | $564 | $23 |
| Evaluation of cardiac rhythm monitor system | 15 | $557 | $28 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 16 | $457 | $10 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 24 | $240 | $10 |
2016: 14 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 12 | $11,364 | $874 |
| Return visit (30+ min) | 85 | $8,632 | $80 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 23 | $7,379 | $307 |
| Short return visit (20+ min) | 102 | $7,185 | $49 |
| New patient visit (45+ min) | 55 | $6,663 | $121 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 19 | $2,174 | $109 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 29 | $1,958 | $47 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 47 | $1,724 | $28 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 103 | $1,694 | $13 |
| Short return visit | 45 | $1,471 | $29 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $845 | $56 |
| Programming of dual lead pacemaker system | 13 | $626 | $45 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 12 | $386 | $23 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 19 | $322 | $17 |
2015: 11 services
| Short return visit (20+ min) | 125 | $12,961 | $51 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 15 | $4,518 | $301 |
| New patient visit (45+ min) | 33 | $3,788 | $115 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 132 | $3,513 | $13 |
| Return visit (30+ min) | 13 | $1,323 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,288 | $59 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 13 | $713 | $51 |
| Short return visit | 19 | $668 | $32 |
| Programming of dual lead pacemaker system | 12 | $577 | $44 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 15 | $480 | $30 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 25 | $433 | $17 |
2014: 12 services
| Short return visit (20+ min) | 123 | $14,593 | $53 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $6,767 | $423 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 20 | $6,299 | $315 |
| New patient visit (45+ min) | 39 | $5,057 | $130 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 123 | $3,486 | $13 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 16 | $1,293 | $50 |
| Return visit (30+ min) | 14 | $1,288 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,170 | $58 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 25 | $952 | $26 |
| Programming of dual lead pacemaker system | 13 | $562 | $43 |
| Short return visit | 12 | $372 | $31 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 12 | $227 | $19 |
2013: 12 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 14 | $8,947 | $639 |
| Short return visit (20+ min) | 91 | $8,692 | $57 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 18 | $5,414 | $301 |
| New patient visit (45+ min) | 41 | $5,241 | $128 |
| Return visit (30+ min) | 51 | $4,868 | $83 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $4,271 | $388 |
| New patient visit (30+ min) | 24 | $2,108 | $88 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 69 | $1,663 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,363 | $57 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,122 | $80 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 17 | $637 | $29 |
| Short return visit | 12 | $447 | $37 |
Medicaid work
$1,552 in 2024
Medicaid paid $1,552 for 188 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | 61 | $680 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 31 | $555 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 15 | $317 |
| Pain severity quantified; no pain present (COA) (ONC) | 16 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 13 | $0 |
| Blood pressure has a systolic value of < 140 and a diastolic value of < 90 | 15 | $0 |
| Documentation that patient is a current non-tobacco user | 37 | $0 |
| 2024 | 188 | 7 | 17 | $1,552 |
| 2023 | 374 | 4 | 27 | $5,227 |
| 2022 | 388 | 4 | 24 | $5,656 |
| 2021 | 230 | 5 | 23 | $2,457 |
| 2020 | 18 | 1 | 14 | $707 |
| 2019 | 98 | 2 | 15 | $1,916 |
| 2018 | 129 | 2 | 19 | $3,792 |
See the largest Medicaid services in earlier years
2023
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 121 | $2,698 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 127 | $1,436 |
| Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | 89 | $882 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 37 | $211 |
2022
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 138 | $3,251 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 156 | $1,725 |
| Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | 56 | $452 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 38 | $228 |
2021
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 44 | $943 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 85 | $748 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 74 | $343 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 13 | $264 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 14 | $160 |
2020
| Short return visit (20+ min) | 18 | $707 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 84 | $1,271 |
| Short return visit (20+ min) | 14 | $645 |
2018
| Return visit (30+ min) | 58 | $2,610 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 71 | $1,182 |
Drugs they prescribed that Part D paid
$253,831
Pharmacies billed $253,831 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 517) in 2024. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 0%.
296 generic and 221 brand-name prescriptions · $253,831 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 141 | $173,157 | $1,228 |
| Xarelto | 58 | $64,296 | $1,109 |
| Flecainide Acetate | 43 | $2,083 | $48 |
| Metoprolol | 81 | $1,850 | $23 |
| Diltiazem 24hr Er (Cd) | 26 | $1,022 | $39 |
See all 7 drugs
| Eliquis | 141 | $173,157 | $1,228 |
| Xarelto | 58 | $64,296 | $1,109 |
| Flecainide Acetate | 43 | $2,083 | $48 |
| Metoprolol | 81 | $1,850 | $23 |
| Diltiazem 24hr Er (Cd) | 26 | $1,022 | $39 |
| Amiodarone | 28 | $881 | $31 |
| Sodium Chloride | 21 | $554 | $26 |
Year by year
| 2024 | 517 | 170 | 0% (0) | 43% | $253,831 |
| 2023 | 809 | 223 | None | 53% | $509,213 |
| 2022 | 940 | 247 | 0% (0) | 50% | $529,116 |
| 2021 | 1,039 | 238 | 0% (0) | 41% | $467,691 |
| 2020 | 1,145 | 253 | 0% (0) | 29% | $348,235 |
| 2019 | 1,197 | 260 | 2% (26) | 26% | $291,929 |
| 2018 | 1,102 | 206 | 4% (48) | 32% | $263,435 |
| 2017 | 1,095 | 202 | 5% (52) | 40% | $216,559 |
| 2016 | 1,177 | 180 | 2% (28) | 42% | $201,067 |
| 2015 | 1,246 | 166 | None | None | $180,264 |
| 2014 | 1,241 | 146 | 1% (14) | 38% | $131,152 |
| 2013 | 977 | 130 | 4% (36) | 31% | $80,208 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Eliquis | 324 | $359,473 | $1,109 |
| Xarelto | 101 | $118,823 | $1,176 |
| Dofetilide | 11 | $8,636 | $785 |
| Quinidine Gluconate | 11 | $3,821 | $347 |
| Metoprolol | 87 | $2,755 | $32 |
| Flecainide Acetate | 31 | $1,644 | $53 |
| Diltiazem 24hr Er (Cd) | 32 | $1,235 | $39 |
| Amiodarone | 25 | $1,109 | $44 |
| Atorvastatin | 17 | $817 | $48 |
| Pantoprazole | 28 | $272 | $10 |
| Diltiazem | 11 | $217 | $20 |
| Lisinopril | 14 | $203 | $14 |
| Losartan | 12 | $194 | $16 |
| Metoprolol | 22 | $175 | $8 |
2022: 16 drugs
| Eliquis | 352 | $370,609 | $1,053 |
| Xarelto | 96 | $105,712 | $1,101 |
| Pradaxa | 11 | $15,042 | $1,367 |
| Dofetilide | 14 | $9,094 | $650 |
| Metoprolol | 119 | $3,631 | $31 |
| Flecainide Acetate | 29 | $1,360 | $47 |
| Diltiazem 24hr Er (Cd) | 42 | $1,142 | $27 |
| Amiodarone | 21 | $1,023 | $49 |
| Atorvastatin | 21 | $324 | $15 |
| Warfarin | 17 | $239 | $14 |
| Metoprolol | 23 | $170 | $7 |
| Losartan | 13 | $147 | $11 |
| Pantoprazole | 22 | $126 | $6 |
| Carvedilol | 17 | $112 | $7 |
| Furosemide | 19 | $68 | $4 |
| Lisinopril | 15 | $59 | $4 |
2021: 20 drugs
| Eliquis | 317 | $316,654 | $999 |
| Xarelto | 63 | $79,486 | $1,262 |
| Pradaxa | 19 | $24,742 | $1,302 |
| Propafenone Hcl Er | 12 | $5,598 | $466 |
| Metoprolol | 148 | $5,420 | $37 |
| Amiodarone | 20 | $2,543 | $127 |
| Midodrine | 15 | $2,473 | $165 |
| Flecainide Acetate | 42 | $1,889 | $45 |
| Diltiazem 24hr Er (Cd) | 50 | $1,513 | $30 |
| Digoxin | 24 | $770 | $32 |
| Losartan | 29 | $300 | $10 |
| Atorvastatin | 19 | $265 | $14 |
| Warfarin | 12 | $257 | $21 |
| Diltiazem | 11 | $187 | $17 |
| Metoprolol | 35 | $184 | $5 |
| Pantoprazole | 22 | $169 | $8 |
| Carvedilol | 20 | $120 | $6 |
| Amlodipine Besylate | 19 | $88 | $5 |
| Furosemide | 22 | $85 | $4 |
| Lisinopril | 19 | $81 | $4 |
2020: 24 drugs
| Eliquis | 221 | $229,803 | $1,040 |
| Xarelto | 56 | $57,865 | $1,033 |
| Pradaxa | 12 | $14,297 | $1,191 |
| Amiodarone | 48 | $6,631 | $138 |
| Metoprolol | 172 | $6,144 | $36 |
| Flecainide Acetate | 49 | $2,926 | $60 |
| Bystolic | 11 | $2,764 | $251 |
| Diltiazem 24hr Er (Cd) | 79 | $2,650 | $34 |
| Sotalol | 18 | $1,095 | $61 |
| Warfarin | 35 | $827 | $24 |
| Cartia Xt | 13 | $455 | $35 |
| Digoxin | 11 | $423 | $38 |
| Carvedilol | 53 | $422 | $8 |
| Atorvastatin | 24 | $370 | $15 |
| Clopidogrel | 15 | $259 | $17 |
| Losartan | 26 | $236 | $9 |
| Pantoprazole | 27 | $191 | $7 |
| Lisinopril | 38 | $182 | $5 |
| Metoprolol | 33 | $181 | $5 |
| Furosemide | 35 | $137 | $4 |
| Amlodipine Besylate | 18 | $123 | $7 |
| Simvastatin | 18 | $93 | $5 |
| Atenolol | 13 | $35 | $3 |
| Hydrochlorothiazide | 11 | $25 | $2 |
2019: 23 drugs
| Eliquis | 168 | $172,399 | $1,026 |
| Xarelto | 68 | $54,396 | $800 |
| Pradaxa | 23 | $19,309 | $840 |
| Dofetilide | 11 | $9,826 | $893 |
| Metoprolol | 176 | $6,172 | $35 |
| Amiodarone | 75 | $5,734 | $76 |
| Bystolic | 12 | $2,813 | $234 |
| Diltiazem 24hr Er (Cd) | 88 | $2,384 | $27 |
| Flecainide Acetate | 46 | $2,187 | $48 |
| Sotalol | 14 | $743 | $53 |
| Hydrocodone-Acetaminophen | 15 | $537 | $36 |
| Carvedilol | 52 | $379 | $7 |
| Losartan | 36 | $359 | $10 |
| Atorvastatin | 25 | $355 | $14 |
| Warfarin | 13 | $328 | $25 |
| Metoprolol | 54 | $319 | $6 |
| Lisinopril | 45 | $286 | $6 |
| Pantoprazole | 27 | $154 | $6 |
| Simvastatin | 23 | $148 | $6 |
| Furosemide | 35 | $132 | $4 |
| Clopidogrel | 15 | $117 | $8 |
| Diltiazem | 17 | $111 | $7 |
| Amlodipine Besylate | 12 | $33 | $3 |
2018: 22 drugs
| Eliquis | 180 | $152,325 | $846 |
| Xarelto | 56 | $41,940 | $749 |
| Dofetilide | 35 | $16,078 | $459 |
| Pradaxa | 13 | $9,270 | $713 |
| Metoprolol | 147 | $5,499 | $37 |
| Amiodarone | 79 | $3,201 | $41 |
| Bystolic | 14 | $2,649 | $189 |
| Diltiazem 24hr Er (Cd) | 50 | $1,930 | $39 |
| Flecainide Acetate | 23 | $1,468 | $64 |
| Digoxin | 14 | $822 | $59 |
| Gabapentin | 11 | $814 | $74 |
| Hydrocodone-Acetaminophen | 18 | $689 | $38 |
| Metoprolol | 64 | $315 | $5 |
| Lisinopril | 38 | $275 | $7 |
| Pantoprazole | 30 | $223 | $7 |
| Warfarin | 12 | $218 | $18 |
| Atorvastatin | 11 | $213 | $19 |
| Carvedilol | 30 | $202 | $7 |
| Losartan | 21 | $195 | $9 |
| Furosemide | 48 | $154 | $3 |
| Clopidogrel | 13 | $125 | $10 |
| Simvastatin | 17 | $49 | $3 |
2017: 22 drugs
| Eliquis | 200 | $136,130 | $681 |
| Xarelto | 37 | $26,809 | $725 |
| Dofetilide | 28 | $17,859 | $638 |
| Pradaxa | 18 | $9,024 | $501 |
| Metoprolol | 115 | $5,559 | $48 |
| Amiodarone | 69 | $2,842 | $41 |
| Diltiazem 12hr Er | 20 | $2,222 | $111 |
| Diltiazem 24hr Er | 52 | $1,742 | $34 |
| Flecainide Acetate | 24 | $1,647 | $69 |
| Bystolic | 12 | $1,491 | $124 |
| Digoxin | 26 | $1,390 | $53 |
| Methadone | 19 | $929 | $49 |
| Lisinopril | 48 | $545 | $11 |
| Metoprolol | 82 | $532 | $6 |
| Cartia Xt | 19 | $506 | $27 |
| Carvedilol | 31 | $477 | $15 |
| Losartan | 42 | $428 | $10 |
| Atorvastatin | 15 | $336 | $22 |
| Clopidogrel | 23 | $281 | $12 |
| Furosemide | 65 | $252 | $4 |
| Pantoprazole | 13 | $204 | $16 |
| Oxycodone-Acetaminophen | 17 | $94 | $6 |
2016: 21 drugs
| Eliquis | 207 | $113,449 | $548 |
| Xarelto | 45 | $22,413 | $498 |
| Pradaxa | 46 | $20,405 | $444 |
| Tikosyn | 11 | $15,325 | $1,393 |
| Amiodarone | 103 | $7,360 | $71 |
| Metoprolol | 107 | $4,807 | $45 |
| Diltiazem 24hr Er | 81 | $2,247 | $28 |
| Flecainide Acetate | 37 | $1,358 | $37 |
| Digoxin | 23 | $1,228 | $53 |
| Metoprolol | 109 | $738 | $7 |
| Carvedilol | 39 | $391 | $10 |
| Atorvastatin | 16 | $324 | $20 |
| Losartan | 29 | $286 | $10 |
| Lisinopril | 46 | $284 | $6 |
| Furosemide | 69 | $225 | $3 |
| Pantoprazole | 17 | $199 | $12 |
| Clopidogrel | 23 | $189 | $8 |
| Potassium Chloride | 14 | $181 | $13 |
| Simvastatin | 11 | $74 | $7 |
| Atenolol | 14 | $56 | $4 |
| Cephalexin | 11 | $37 | $3 |
2015: 21 drugs
| Eliquis | 135 | $70,026 | $519 |
| Pradaxa | 84 | $31,738 | $378 |
| Tikosyn | 29 | $24,332 | $839 |
| Xarelto | 46 | $21,834 | $475 |
| Amiodarone | 118 | $10,999 | $93 |
| Metoprolol | 128 | $5,139 | $40 |
| Digoxin | 33 | $1,559 | $47 |
| Diltiazem 24hr Er | 48 | $1,395 | $29 |
| Flecainide Acetate | 32 | $1,322 | $41 |
| Metoprolol | 147 | $860 | $6 |
| Potassium Chloride | 20 | $463 | $23 |
| Losartan | 34 | $389 | $11 |
| Atorvastatin | 22 | $376 | $17 |
| Warfarin | 15 | $357 | $24 |
| Carvedilol | 37 | $354 | $10 |
| Lisinopril | 60 | $350 | $6 |
| Verapamil Er | 12 | $288 | $24 |
| Furosemide | 77 | $253 | $3 |
| Pantoprazole | 18 | $243 | $14 |
| Simvastatin | 15 | $124 | $8 |
| Amlodipine Besylate | 25 | $83 | $3 |
2014: 20 drugs
| Eliquis | 118 | $42,109 | $357 |
| Pradaxa | 94 | $34,997 | $372 |
| Tikosyn | 30 | $19,990 | $666 |
| Xarelto | 20 | $6,622 | $331 |
| Amiodarone | 92 | $6,321 | $69 |
| Metoprolol | 91 | $4,375 | $48 |
| Atorvastatin | 31 | $1,611 | $52 |
| Metoprolol | 199 | $1,255 | $6 |
| Digoxin | 28 | $1,209 | $43 |
| Diltiazem 24hr Er | 31 | $1,028 | $33 |
| Flecainide Acetate | 29 | $924 | $32 |
| Potassium Chloride | 32 | $751 | $23 |
| Warfarin | 23 | $588 | $26 |
| Carvedilol | 41 | $417 | $10 |
| Furosemide | 104 | $401 | $4 |
| Pantoprazole | 24 | $392 | $16 |
| Lisinopril | 51 | $386 | $8 |
| Simvastatin | 18 | $295 | $16 |
| Losartan | 19 | $187 | $10 |
| Amlodipine Besylate | 23 | $120 | $5 |
2013: 19 drugs
| Pradaxa | 77 | $24,307 | $316 |
| Eliquis | 51 | $14,278 | $280 |
| Xarelto | 34 | $9,942 | $292 |
| Tikosyn | 13 | $6,380 | $491 |
| Metoprolol | 47 | $2,479 | $53 |
| Atorvastatin | 43 | $2,070 | $48 |
| Flecainide Acetate | 35 | $1,076 | $31 |
| Warfarin | 51 | $918 | $18 |
| Amiodarone | 60 | $850 | $14 |
| Clopidogrel | 13 | $743 | $57 |
| Metoprolol | 116 | $570 | $5 |
| Pantoprazole | 34 | $513 | $15 |
| Potassium Chloride | 18 | $503 | $28 |
| Carvedilol | 48 | $495 | $10 |
| Lisinopril | 55 | $288 | $5 |
| Furosemide | 65 | $277 | $4 |
| Amlodipine Besylate | 32 | $251 | $8 |
| Losartan | 13 | $244 | $19 |
| Digox | 16 | $216 | $13 |
Money from drug and device companies
$6,139 in 2025
| 2025 | 10 | 63 | None | $6,139 |
| 2024 | 14 | 114 | $7,604 | $21,574 |
| 2023 | 7 | 105 | $7,154 | $17,823 |
| 2022 | 13 | 62 | $4,320 | $10,911 |
| 2021 | 14 | 83 | $19,386 | $24,744 |
| 2020 | 8 | 56 | $7,296 | $11,669 |
| 2019 | 10 | 91 | $13,500 | $28,730 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Ensite | $3,012 | 31 payments
|
| Biosense Webster | Carto 3 | $1,053 | 6 payments
|
| Medtronic | Affera Mapping System | $974 | 13 payments
|
| Boston Scientific | Watchman Flx | $450 | 6 payments
|
| AtriCure | Epi-Sense Guided Coagulation System With Visitrax | $217 | 2 payments
|
| Impulse Dynamics (USA) | Optimizer | $178 | 1 payment
|
See all 63 published payments
| Abbott Laboratories | Meals · 2025-12-31 | Cardiomems | $158 |
| Biosense Webster | Meals · 2025-12-12 | Carto 3 | $147 |
| Medtronic | Meals · 2025-12-12 | Aurora Ev-Icd Mri Surescan | $113 |
| Medtronic | Meals · 2025-12-01 | Affera Mapping System | $112 |
| Abbott Laboratories | Meals · 2025-11-11 | Amplatzer Amulet | $23 |
| Biosense Webster | Travel · 2025-11-07 | Carto 3 | $216 |
| Philips North America | Meals · 2025-10-30 | Igt Devices Undivided | $26 |
| Biosense Webster | Travel · 2025-10-20 | Carto 3 | $337 |
| Medtronic | Meals · 2025-10-14 | Aurora Ev-Icd Mri Surescan | $58 |
| Biosense Webster | Meals · 2025-10-09 | Carto 3 | $141 |
| Impulse Dynamics (USA) | Meals · 2025-10-07 | Optimizer | $178 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-06 | Camzyos | $123 |
| Boston Scientific | Meals · 2025-10-02 | Watchman Flx | $109 |
| Medtronic | Meals · 2025-10-02 | Aurora Ev-Icd Mri Surescan | $9 |
| Medtronic | Meals · 2025-10-01 | Omniasecure Mri Surescan | $82 |
| AtriCure | Meals · 2025-09-05 | Epi-Sense Guided Coagulation System With Visitrax | $92 |
| Medtronic | Meals · 2025-08-26 | Affera Mapping System | $97 |
| Medtronic | Meals · 2025-08-15 | Cobalt Dr Mri Surescan | $57 |
| Abbott Laboratories | Meals · 2025-08-14 | Ensite | $108 |
| Abbott Laboratories | Meals · 2025-08-07 | Cardiomems | $33 |
| Medtronic | Meals · 2025-08-02 | Cobalt Dr Mri Surescan | $33 |
| Medtronic | Meals · 2025-07-28 | Cobalt Dr Mri Surescan | $40 |
| Medtronic | Meals · 2025-07-27 | Cobalt Dr Mri Surescan | $30 |
| Boston Scientific | Meals · 2025-07-24 | Lux-Dx Insertable Cardiac Monitor | $120 |
| Medtronic | Meals · 2025-07-18 | Affera Mapping System | $94 |
| Boston Scientific | Meals · 2025-07-17 | Watchman Flx | $87 |
| Boston Scientific | Meals · 2025-07-16 | Watchman Flx | $16 |
| AtriCure | Meals · 2025-07-15 | Epi-Sense Guided Coagulation System With Visitrax | $125 |
| Abbott Laboratories | Meals · 2025-07-15 | Cardiomems | $31 |
| Boston Scientific | Meals · 2025-07-10 | Watchman Flx | $23 |
| Biosense Webster | Meals · 2025-07-09 | Carto 3 | $73 |
| Medtronic | Meals · 2025-07-08 | Selectsecure | $105 |
| Abbott Laboratories | Meals · 2025-06-23 | Ensite | $123 |
| Abbott Laboratories | Meals · 2025-06-09 | Cardiomems | $34 |
| Abbott Laboratories | Meals · 2025-06-05 | Gallant | $86 |
| Abbott Laboratories | Meals · 2025-06-02 | Ensite | $142 |
| Abbott Laboratories | Meals · 2025-05-16 | Ensite | $187 |
| Abbott Laboratories | Meals · 2025-05-09 | Ensite | $189 |
| Biosense Webster | Meals · 2025-05-02 | Carto 3 | $140 |
| Medtronic | Meals · 2025-04-25 | Pulseselect | $143 |
| Abbott Laboratories | Meals · 2025-04-24 | Ensite | $87 |
| Abbott Laboratories | Travel · 2025-04-07 | Aveir | $444 |
| Abbott Laboratories | Meals · 2025-03-31 | Aveir | $16 |
| Abbott Laboratories | Meals · 2025-03-27 | Cardiomems | $23 |
| Abbott Laboratories | Meals · 2025-03-24 | Ensite | $64 |
| Abbott Laboratories | Meals · 2025-03-18 | Ensite | $30 |
| Abbott Laboratories | Meals · 2025-03-07 | Assurity | $15 |
| Cardiva Medical | Meals · 2025-03-06 | Cardiva Vascade Mvp Vvcs 6-12f | $89 |
| Boston Scientific | Meals · 2025-02-01 | Farapulse | $95 |
| Abbott Laboratories | Meals · 2025-01-23 | Tacticath Ablation Catheter, Sensor Enabled | $30 |
| Abbott Laboratories | Meals · 2025-01-20 | Aveir | $145 |
| Abbott Laboratories | Meals · 2025-01-20 | Jot Dx | $11 |
| Abbott Laboratories | Meals · 2025-01-20 | Jot Dx | $49 |
| Abbott Laboratories | Travel · 2025-01-16 | Tacticath Ablation Catheter, Sensor Enabled | $204 |
| Abbott Laboratories | Travel · 2025-01-16 | Tacticath Ablation Catheter, Sensor Enabled | $209 |
| Abbott Laboratories | Travel · 2025-01-16 | Tacticath Ablation Catheter, Sensor Enabled | $140 |
| Merck Sharp & Dohme | Meals · 2025-01-15 | Verquvo | $18 |
| Abbott Laboratories | Meals · 2025-01-13 | Aveir | $42 |
| Abbott Laboratories | Meals · 2025-01-13 | Aveir | $34 |
| Abbott Laboratories | Meals · 2025-01-09 | Tacticath Ablation Catheter, Sensor Enabled | $20 |
| Abbott Laboratories | Travel · 2025-01-09 | Tacticath Ablation Catheter, Sensor Enabled | $186 |
| Abbott Laboratories | Travel · 2025-01-09 | Tacticath Ablation Catheter, Sensor Enabled | $9 |
| Abbott Laboratories | Meals · 2025-01-08 | Ensite | $139 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $21,574
| Abbott Laboratories | Gallant | $9,770 | 39 payments
|
| Medtronic | Evera Mri Xt Dr Surescan | $6,387 | 35 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $3,043 | 4 payments
|
| Boston Scientific | Emblem Mri S-Icd | $540 | 15 payments
|
| Haemonetics | None | $500 | 1 payment
|
| Atricure | Epi-Sense Guided Coagulation System With Visitrax | $469 | 4 payments
|
| Biosense Webster | Carto 3 | $336 | 6 payments
|
| Janssen Pharmaceuticals | Xarelto | $162 | 3 payments
|
| Philips North America | (9520) Igt Devices Und | $141 | 1 payment
|
| Cardiva Medical | Ensoetm | $129 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $31 | 1 payment
|
| Abiomed | Impella | $29 | 1 payment
|
| Vital Connect | Vitalpatch Rtm | $21 | 1 payment
|
| CVRx | Barostim Neo System | $19 | 1 payment
|
2023: $17,823
| Abbott Laboratories | Aveir | $7,639 | 26 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $3,178 | 5 payments
|
| Medtronic | Micra | $2,704 | 28 payments
|
| Atricure | Epi-Sense Guided Coagulation System With Visitrax | $2,517 | 13 payments
|
| Boston Scientific | Resonate El Icd Vr | $995 | 18 payments
|
| Biosense Webster | Carto 3 | $758 | 14 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $32 | 1 payment
|
2022: $10,911
| E.R. Squibb & Sons L.L.C. | Eliquis | $4,059 | 3 payments
|
| Medical Device Business Services | Carto 3 | $2,569 | 7 payments
|
| Boston Scientific | Watchman Access System | $1,742 | 22 payments
|
| Biosense Webster | Carto 3 | $749 | 10 payments
|
| Abbott Laboratories | Mitraclip | $738 | 6 payments
|
| Alexion Pharmaceuticals | Andexxa | $365 | 1 payment
|
| Medtronic | Cobalt Dr Mri Surescan | $332 | 5 payments
|
| AtriCure | Synergy Ablation System | $202 | 2 payments
|
| Pfizer | Eliquis | $68 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $49 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $19 | 1 payment
|
| iRhythm Technologies | Zio Xt Patch | $13 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $6 | 1 payment
|
2021: $24,744
| Abbott Laboratories | Confirm Rx | $7,689 | 28 payments
|
| Alexion Pharmaceuticals | Andexxa | $4,125 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $3,767 | 2 payments
|
| Medical Device Business Services | Carto 3 | $3,000 | 3 payments
|
| Baylis Medical Company | Nrg Transseptal Needle | $2,250 | 1 payment
|
| Biosense Webster | Carto 3 | $1,641 | 5 payments
|
| Boston Scientific | Watchman | $1,351 | 25 payments
|
| Medtronic | Micra | $419 | 10 payments
|
| Stryker | N/A | $124 | 1 payment
|
| Pfizer | Eliquis | $123 | 1 payment
|
| Philips Electronics North America | (9278) Bridge | $118 | 1 payment
|
| KLS-Martin L.P. | None | $99 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $23 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $14 | 1 payment
|
2020: $11,669
| Boston Scientific | General - Therapies | $5,804 | 30 payments
|
| Abbott Laboratories | Ensite Cardiac Mapping System | $2,754 | 11 payments
|
| Medical Device Business Services | Carto 3 System | $2,741 | 6 payments
|
| Biosense Webster | Carto 3 System | $147 | 3 payments
|
| Biotronik | None | $133 | 2 payments
|
| Medtronic Vascular | Cobalt | $40 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $37 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $14 | 1 payment
|
2019: $28,730
| Biotronik | None | $9,652 | 12 payments
|
| Medical Device Business Services | Carto 3 System | $8,814 | 17 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $7,199 | 4 payments
|
| Boston Scientific | Rhythmia | $1,199 | 23 payments
|
| Biosense Webster | Carto 3 System | $1,027 | 17 payments
|
| Abbott Laboratories | Quadra Assura Crt Defibrillator | $424 | 7 payments
|
| AtriCure | Epi-Sense Guided Coagulation Sys | $282 | 4 payments
|
| Medtronic Vascular | Azure | $83 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $26 | 2 payments
|
| Amarin Pharma | Vascepa | $25 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| BOSTON SCIENTIFIC CORPORATION · Newton Af · 2022 | Their institution | $11,888 |
| ATRICURE, INC. · Left Atrial Appendage Ligation With the Lariat Suture Delivery System As Adjunctive Therapy To Pulmonary Vein Isolation for Persistent Or Longstanding Persistant Atrial Fibrillation (Amaze Study) · 2020 | Their institution | $10,726 |
| ATRICURE, INC. · Left Atrial Appendage Ligation With the Lariat Suture Delivery System As Adjunctive Therapy To Pulmonary Vein Isolation for Persistent Or Longstanding Persistant Atrial Fibrillation (Amaze Study) · 2021 | Their institution | $10,400 |
| Biosense Webster, Inc. · Safety and Feasibility of Ultra-Low Fluoroscopic Atrial Fibrillation Ablation: A Retrospective Analysis · 2020 | Their institution | $10,000 |
| Boston Scientific Corporation · Newton Af · 2023 | Their institution | $5,797 |
| Boston Scientific Corporation · Newton Af · 2024 | Their institution | $4,700 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1669431615
- Licence
- HI MD16085
- Trained
- Georgetown University School of Medicine, 2003
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 550 South Beretania Street, Suite 601, Honolulu, HI, 96813
- NPI first listed
- 2006-03-20
- NPI last updated
- 2025-07-03
- NPI record certified
- 2025-07-03
This is when the NPI record was last certified, not a medical board exam.